Promacta is an anti-diabetic drug owned by Novartis. It contains the active ingredient eltrombopag olamine and was first authorized for market use on 20 November, 2008. Promacta has a total of 16 patents, out of which 4 have expired.
The generic versions of Promacta are projected to be released after 01 February, 2028. This is because the last patent for Promacta (US8828430*PED) expires on this date. Furthermore, as patents give the patent holder exclusive rights to produce the drug for a certain period of time, generic manufacturers often have to wait until the patents expire before they can start producing generic versions.
Promacta is primarily used to treat conditions that cause low blood platelet counts, such as chronic immune thrombocytopenia and severe aplastic anemia. It is also utilized to boost platelet counts in patients with chronic hepatitis C, allowing for the initiation and maintenance of interferon-based therapy.
Promacta has 16 patents, of which the last one expires on 01 February, 2028. This patent, US8828430*PED, is pivotal for the production of Promacta generic. Below are the details of the patent: